Mainz Biomed (MYNZ) News Today $1.98 +0.13 (+7.03%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.88 -0.10 (-5.05%) As of 07/15/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MYNZ Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening AcquisitionJuly 15 at 8:43 AM | globenewswire.comMainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening AcquisitionJuly 15 at 8:43 AM | globenewswire.comMainz Biomed BV News (MYNZ) - Investing.comJuly 4, 2025 | investing.comMainz BioMed NV: Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening TestJune 25, 2025 | finanznachrichten.deMainz Biomed BV Aktie | MYNZ Kurs | Realtime - Investing.comJune 25, 2025 | de.investing.comMainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening TestJune 25, 2025 | globenewswire.comPromising Advancements in Cancer Diagnostics Propel Mainz Biomed B.V. to a Buy RatingJune 11, 2025 | tipranks.comMainz BioMed NV: Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer ProjectJune 10, 2025 | finanznachrichten.deMainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer ProjectJune 10, 2025 | finance.yahoo.comMainz Biomed Initiates Feasibility Phase for Non-Invasive Pancreatic Cancer Screening Test in PancAlert ProjectJune 10, 2025 | quiverquant.comQMainz Biomed N.V. Shareholders Approve Key Proposals at Annual MeetingJune 5, 2025 | tipranks.comMainz Biomed N.V. Secures $4 Million Through Securities OfferingMay 21, 2025 | tipranks.comMainz Biomed prices $4M securities offeringMay 20, 2025 | seekingalpha.comMainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and WarrantsMay 19, 2025 | investing.comMainz Biomed Announces Pricing of $4 Million Follow-On Offering and Warrant AmendmentsMay 19, 2025 | quiverquant.comQMainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and WarrantsMay 19, 2025 | globenewswire.comMainz Biomed wird bis Ende Sommer Update zur Darmkrebs-Screening-Studie gebenMay 16, 2025 | de.investing.comMainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical StudyMay 16, 2025 | globenewswire.comMainz Biomed launches public offering of units and warrantsMay 16, 2025 | msn.comMainz Biomed kündigt Jahreshauptversammlung für den 2. Juni anMay 2, 2025 | de.investing.comMainz Biomed Prepares for June 2025 Annual General MeetingMay 2, 2025 | tipranks.comMainz Biomed advances in FDA approval for CRC testApril 29, 2025 | investing.comMainz Biomed Enters into Technology Partnership with EDX Medical GroupApril 29, 2025 | globenewswire.comMainz BioMed NV: Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket ApprovalApril 28, 2025 | finanznachrichten.deMainz Biomed N.V. Reports Q1 2025 Accomplishments and FDA Premarket Approval ProgressApril 28, 2025 | quiverquant.comQMainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket ApprovalApril 28, 2025 | globenewswire.comMainz Biomed (MYNZ) Sees Revenue Surge Amid Strong Demand for ColoAlertApril 27, 2025 | gurufocus.comMainz Biomed (MYNZ) Advances Colorectal Cancer Test With New StudyApril 27, 2025 | gurufocus.comMainz Biomed BV: EPS verfehlt Schätzungen um 4,91 $ - Umsatz besser als erwartetApril 23, 2025 | de.investing.comMainz Biomed Narrows Its Losses, Grows Revenue For Full Year 2024April 15, 2025 | benzinga.comMainz Biomed-Aktie stürzt auf 52-Wochen-Tief von 2,65 US-DollarApril 5, 2025 | de.investing.comMainz Biomed-Aktie stürzt auf 52-Wochen-Tief von 2,65 US-DollarApril 5, 2025 | de.investing.comMainz Biomed Reports 2024 Financial Results and Provides Corporate UpdateApril 2, 2025 | markets.businessinsider.comMainz Biomed reports FY24 EPS ($22.36) vs ($64.76) last yearApril 1, 2025 | markets.businessinsider.comEQS-News: Mainz Biomed Reports 2024 Financial Results and Provides Corporate UpdateApril 1, 2025 | markets.businessinsider.comMainz Biomed Reports 2024 Financial Success and Strategic AdvancesApril 1, 2025 | tipranks.comMainz Biomed Enrolls First Patient In EAArly DETECT 2 Study To Advance Colorectal Cancer TestMarch 29, 2025 | nasdaq.comMainz Biomed enrolls first patient in its eAArly DETECT 2 studyMarch 28, 2025 | markets.businessinsider.comBuy Rating for Mainz Biomed B.V. Driven by Promising CRC Screening Advancements and Strategic PartnershipsMarch 28, 2025 | tipranks.comMainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical StudyMarch 27, 2025 | globenewswire.comStrategic Collaboration and Innovative Biomarkers Drive Buy Rating for Mainz BiomedMarch 21, 2025 | tipranks.comMainz Biomed Licenses MRNA Biomarkers For Non-Invasive Pancreatic Cancer Screening TestMarch 15, 2025 | nasdaq.comEQS-News: Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic CancerMarch 13, 2025 | markets.businessinsider.comMainz Biomed, Liquid Biosciences make discovery of mRNA biomarkersMarch 13, 2025 | markets.businessinsider.comMainz Biomed’s Breakthrough in Pancreatic Cancer DetectionMarch 13, 2025 | tipranks.comMainz Biomed Signs Exclusive Licensing Agreement with Liquid Biosciences for Novel mRNA Biomarkers in Pancreatic Cancer DetectionMarch 13, 2025 | quiverquant.comQMainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic CancerMarch 13, 2025 | globenewswire.comMainz Biomed supports Colorectal Cancer Awareness MonthMarch 4, 2025 | markets.businessinsider.comEQS-News: Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to PreventionMarch 3, 2025 | markets.businessinsider.comColorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to PreventionMarch 3, 2025 | globenewswire.com Get Mainz Biomed News Delivered to You Automatically Sign up to receive the latest news and ratings for MYNZ and its competitors with MarketBeat's FREE daily newsletter. Email Address MYNZ Media Mentions By Week MYNZ Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MYNZ News Sentiment▼-0.660.97▲Average Medical News Sentiment MYNZ News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MYNZ Articles This Week▼32▲MYNZ Articles Average Week Get Mainz Biomed News Delivered to You Automatically Sign up to receive the latest news and ratings for MYNZ and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies FibroBiologics News Tempest Therapeutics News ALX Oncology News Q32 Bio News Cadrenal Therapeutics News Tenax Therapeutics News Cara Therapeutics News BioAtla News Sol-Gel Technologies News Lisata Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MYNZ) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.